Sector ratings Virax Biolabs Group Limited

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 05/06/2026 BST			5-day change	1st Jan Change
0.2125 ^USD	+7.27%		+12.37%	-38.55%

05-26	Virax Biolabs Group Limited Reports Positive Early Clinical Data for Viraximmune in Long Covid and Related Post-Acute Infection Syndromes	CI
03-18	Virax Biolabs Group Limited Approves Fourth Amended and Restated Memorandum and Articles of Association	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
VIRAX BIOLABS GROUP LIMITED	3.95M	-	-	-		-	-
LONZA GROUP AG	43.52B		AAA
REVOLUTION MEDICINES, INC.	33.1B	-	B	-		-
IQVIA HOLDINGS INC.	31.19B		AAA
BEONE MEDICINES AG	31.12B		-
CELLTRION, INC.	25.35B		A
ASCENDIS PHARMA A/S	13.59B	-	-	-		-		-
EUROFINS SCIENTIFIC SE	13.28B		AA
MEDPACE HOLDINGS, INC.	13.1B		BBB
IONIS PHARMACEUTICALS, INC.	12.42B	-	A	-		-
ICON PUBLIC LIMITED COMPANY	11.7B		AAA
REGENCELL BIOSCIENCE HOLDINGS LIMITED	10.98B	-	-	-	-	-	-	-
TEMPUS AI, INC.	9.38B		A			-
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	8.95B		AA
BIO-TECHNE CORPORATION	8.33B		AA
ABIVAX	7.78B	-	BBB	-		-
QIAGEN N.V.	7.77B		AAA
PRAXIS PRECISION MEDICINES, INC.	7.38B	-	B	-		-
ALKERMES PLC	7.23B		A
APOGEE THERAPEUTICS, INC.	6.81B	-	B	-		-
Average	15.15B		A
Weighted average by Cap.			A